Annual exposure of the Swiss population from medical imaging in 2018

Nationwide surveys on radiation dose to the population from medical imaging are recommended in order to follow trends in population exposure. The goal of the 2018 survey was to investigate the current exposure. The invoice coding information was collected in five university hospitals and large clinics. To improve the estimation of the effective dose delivered in computed tomography (CT), we collected dose data from different Dose Archiving Communication Systems. On average, we found that 1.2 radiological examinations per year and per inhabitant were performed. Dental radiography was the most frequent examination (48% of all the X-ray examinations), followed by conventional radiography (36%) and CT (11%). The average annual effective dose was estimated to be 1.48 mSv per inhabitant, with CT representing 64% of that dose. Our results show that the exposure of the Swiss population from medical imaging has remained stable since 2013, despite a 15% increase in the number of CT examinations

: Quels changements après l’arasement des barrages de Vezins et la Roche-qui-Boit ?

Volet 4 (sociogéographique) du Programme de suivi scientifique de l'arasement des barrages de la Sélun

: Quels changements après l’arasement des barrages de Vezins et la Roche-qui-Boit ?

Volet 4 (sociogéographique) du Programme de suivi scientifique de l'arasement des barrages de la Sélun

La migration des jeunes: quelles mobilités? Quels ancrages?

Ce numéro d’Enfances Familles Générations porte sur les enjeux de la mobilité et de la migration des jeunes adultes. Les articles traitent, notamment, de la mobilité dans le cadre de la poursuite d’études, mais aussi de la construction identitaire en contexte migratoire. Un article Hors thème complète ce dossier thématique. Il aborde les changements dans la maternité en milieu populaire dans la région Nord-est du Brésil

WHO O2CoV2: oxygen requirements and respiratory support in patients with COVID-19 in low-and-middle income countries—protocol for a multicountry, prospective, observational cohort study

Introduction SARS-CoV-2 has been identified as the cause of the disease officially named COVID-19, primarily a respiratory illness. COVID-19 was characterised as a pandemic on 11 March 2020. It has been estimated that approximately 20% of people with COVID-19 require oxygen therapy. Oxygen has been listed on the WHO Model List of Essential Medicines List and Essential Medicines List for Children for almost two decades. The COVID-19 pandemic has highlighted, more than ever, the acute need for scale-up of oxygen therapy. Detailed data on the use of oxygen therapy in low-and-middle income countries at the patient and facility level are needed to target interventions better globally.Methods and analysis We aim to describe the requirements and use of oxygen at the facility and patient level of approximately 4500 patients with COVID-19 in 30 countries. Our objectives are specifically to characterise type and duration of different modalities of oxygen therapy delivered to patients; describe demographics and outcomes of hospitalised patients with COVID-19; and describe facility-level oxygen production and support. Primary analyses will be descriptive in nature. Respiratory support transitions will be described in Sankey plots, and Kaplan-Meier models will be used to estimate probability of each transition. A multistate model will be used to study the course of hospital stay of the study population, evaluating transitions of escalating respiratory support transitions to the absorbing states.Ethics and dissemination WHO Ad Hoc COVID-19 Research Ethics Review Committee (ERC) has approved this global protocol. When this protocol is adopted at specific country sites, national ERCs may make require adjustments in accordance with their respective national research ethics guidelines. Dissemination of this protocol and global findings will be open access through peer-reviewed scientific journals, study website, press and online media.Trial registration number NCT04918875